Advertisement
House passes insurer, PBM anti-gag clause bills

House passes insurer, PBM anti-gag clause bills

By Susannah Luthi  |  September 25, 2018

The U.S. House of Representatives and Senate have both passed measures to halt the use of "gag clauses" by insurers and pharmacy benefit managers. President Donald Trump is expected to sign the bills soon.

Drug prices going up despite Trump promise

Drug prices going up despite Trump promise

By Associated Press  |  September 25, 2018

An analysis of brand-name prescription drug prices shows it's been business as usual for drugmakers, with far more price hikes than cuts. The number of increases slowed somewhat and were not quite as steep as in past years.

Gilead to launch generic versions of hepatitis C drugs

Gilead to launch generic versions of hepatitis C drugs

By Alex Kacik  |  September 24, 2018

Gilead will start selling the generics for chronic hepatitis C in January at a $24,000 list price, a significant discount compared to the price for its branded alternatives, which can cost nearly $100,000 for a full course of treatment.

Generic competition not a cure-all for high drug prices

Generic competition not a cure-all for high drug prices

By Alex Kacik  |  June 12, 2018

Although more generic drugs are coming through the pipeline, generic competition won't affect 46% of the estimated sales revenue of the top 100 drugs through 2023, according to a new report.

Health system-led drug company garners strong provider support

Health system-led drug company garners strong provider support

By Alex Kacik  |  May 24, 2018

Eighty percent of nearly 750 providers, payers and pharmaceutical companies polled said they are optimistic that the new health system-led generic-drug company will change the status quo, and 90% said they would buy drugs from it, according to a new survey.

Advertisement
X

Subscribe and SAVE 50%

View our best offer
Subscribe to Print